Modality
Bispecific Ab
MOA
MDM2i
Target
Nectin-4
Pathway
Checkpoint
FSGSAsthmaNSCLC
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
Sep 2017
→ Apr 2031
Phase 1Current
NCT04883012
339 pts·Asthma
2017-09→2029-01·Not yet recruiting
NCT06800921
2,648 pts·FSGS
2021-01→2031-04·Recruiting
2,987 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-062.8y awayPh2 Data· Asthma
2031-04-165.0y awayPh2 Data· FSGS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Not yet…
P1/2
Recruit…
Catalysts
Ph2 Data
2029-01-06 · 2.8y away
Asthma
Ph2 Data
2031-04-16 · 5.0y away
FSGS
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04883012 | Phase 1/2 | Asthma | Not yet recr... | 339 | Mayo |
| NCT06800921 | Phase 1/2 | FSGS | Recruiting | 2648 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |